Structural biologists at Memorial Sloan-Kettering Cancer Center are collaborating with biochemists and cell biologists at The Rockefeller University to study how cells read genetic instructions imprinted on histones, DNA’s packaging proteins.
New research led by investigators at Memorial Sloan-Kettering Cancer Center sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered.
A new study by researchers at Memorial Sloan-Kettering Cancer Center reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone - the two most prominent sites of lung cancer relapse.
Memorial Sloan-Kettering President Harold Varmus joined lawmakers, scientists, and patients on March 9 at a White House ceremony as President Barack Obama issued an executive order lifting the strict limits on human embryonic stem cell research.
Michael Overholtzer is a recent recruit to Sloan-Kettering Institute’s Cell Biology Program, he pairs this curiosity with a dedication to finding new ways to control disease.
A team of researchers led by Memorial Sloan-Kettering physician-scientist Charles L. Sawyers has reported on the preclinical development and early results from the first clinical trial of a promising new drug for prostate cancer.
Dinshaw J. Patel, a Member in Sloan-Kettering Institute’s Structural Biology Program and incumbent of the Abby Rockefeller Mauzé Chair in Experimental Therapeutics, was elected to the National Academy of Sciences at its 146th annual meeting in April.
Memorial Sloan-Kettering’s Boards of Overseers and Managers have announced the creation of the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs and have named the first two incumbents: Sloan-Kettering Institute’s Grégoire Altan-Bonnet and Songhai Shi.
Jennifer A. Zallen, a member of the Developmental Biology Program in the Sloan-Kettering Institute, has been selected by the Howard Hughes Medical Institute (HHMI) as an Early Career Scientist.
Charles Sawyers, MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center and a Howard Hughes Medical Institute investigator, has been named a “Dream Team” leader by Stand Up To Cancer and will co-lead a collaborative team that will receive $15 million to study targeted therapies to treat women’s cancers.
